First Trust Value Line 100 ETF
JetBlue Airways’ Load Factor Continues to Fall for 3rd Month in a Row
Since JetBlue Airways’ (JBLU) traffic growth has been lagging behind its capacity growth, utilizations have fallen for the third straight month.
What Wall Street Analysts Recommend for JetBlue Airways
As of September 19, 2017, one analyst out of the 15 analysts tracking JetBlue Airways (JBLU) had a “strong buy” recommendation on the stock.
GlaxoSmithKline’s 1Q17 Earnings Surpass Analysts’ Estimates
GlaxoSmithKline (GSK) reported revenue growth of 19% to 7.4 billion pounds in 1Q17.
GlaxoSmithKline’s 1Q17 Estimates: Revenues Expected to Grow
Analysts expect ~16.5% growth in GlaxoSmithKline’s (GSK) 1Q17 revenues to ~7.3 billion pounds following strong product launches, acquired products from Novartis (NVS), and improvement in the supply chain.
Vyzulta May Be a Potent Therapy for Glaucoma in the Future
Vyzulta growth trends On February 24, 2017, Valeant Pharmaceuticals (VRX) refiled its application with the FDA, seeking regulatory approval for Vyzulta (latanoprostene bunod) as a therapy for open-angle glaucoma patients. On July 22, 2016, the company announced that it had received a complete response letter (or CRL) from the FDA related to a previously filed application […]
Siliq May be a Strong Growth Driver for Valeant in 2017
Siliq growth trends On February 15, 2017, the FDA approved injectable biologic therapy Siliq (brodalumab) as a treatment option for moderate-to-severe plaque psoriasis patients. Siliq is for psoriasis patients eligible for systemic therapy or phototherapy, and are not responding sufficiently or have stopped responding to these treatment options. To learn more about Siliq, please refer to What Are […]
Valeant Pharmaceuticals Expects Lower Revenue in 2017
Decline in revenue In fiscal 2017, Valeant Pharmaceuticals (VRX) expects to report revenue of $8.9 billion–$9.1 billion. This projection is based on foreign exchange rates in February 2017. It also includes revenue expected from sales of the company’s skincare products, as Valeant does not expect the divestiture transactions to be completed before the end of 2017. Wall […]
GlaxoSmithKline’s Valuation Compared to Its Peers
As of February 13, 2017, GlaxoSmithKline is trading at a forward PE multiple of 14.2x. That’s slightly lower than the industry average of 15.3x.